Tricyclic compounds as inhibitors of mutant IDH enzymes

US10508108B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Christian Fischer · Natick, US
• Stephane L. Bogen · Somerville, US
• Matthew L. Childers · Medfield, US
• Francesc Xavier Fradera Llinas · Brookline, US
• J. Michael Ellis · Needham, US
• Sara Esposite · Neptune, US
• Dawn Marie Hoffman · Boston, US
• Chunhui Huang · Arlington, US
• Solomon D. Kattar · Arlington, US
• Alexander Kim · Levittown, US
• John W. Lampe · Orange, US
• Michelle R. Machacek · Brookline, US
• Daniel R. McMasters · Brookline, US
• Dann Parker · Cranford, US
• Michael H. Reutershan · Watertown, US
• Nunzio Sciammetta · Sudbury, US
• Pengcheng Patrick Shao · Fanwood, US
• David L. Sloman · Brookline, US
• Wanying Sun · Edison, US
• Feroze Ujjainwalla · Hoboken, US
• Zhicai Wu · Montvale, US
• Yang Yu · Jinan, CN
• Craig R. Gibeau · Holliston, US

Key dates

• Filing date: Dec 1, 2015
• Grant date: Dec 17, 2019
• Expiry date: Dec 1, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R1)═ or —N═; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.